Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 13;12:955866. doi: 10.3389/fonc.2022.955866

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Li, Wu, Li, Dai, Liao, Yang, Chen and Huang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Representative images from three different time points during the follow-up period. The upper row shows images from Case A (T3N2M0) treated with nimotuzumab. (A–C) Baseline DCE-MR images. (A) Slice image. (B) k^trans image. (C) v_e image. (D) T2-weighted image at 3 months of follow-up showing shrinkage of the primary tumor lesion. (E) T2-weighted image at 23 months of follow-up showing complete regression of the primary tumor. The lower row shows images from Case B (T3N2M0) not treated with nimotuzumab. (F–H) Baseline DCE-MR images. (F) Slice image, (G) k^trans image. (H) v_e image. (I) T2-weighted image at 3 months of follow-up showing shrinkage of the primary tumor lesion. (J) T2-weighted image at 12 months of follow-up showing the first recurrence of the disease.